1. Lithium is an effective drug for both treatment and prophylaxis of bipol
ar disorder. However, the mechanism of lithium action is still unknown.
2. The inositol depletion hypothesis is supported by biochemical and behavi
oral data in rats, but primate inositol levels are higher than in rodents a
nd may obviate the effects of depletion.
3. Inhibition of 5HT autoreceptors by lithium is supported by biochemical a
nd behavioral data in rats but would seem more related to lithium's antidep
ressant than to its antimanic or prophylactic effects.
4. Lithium induces increases in levels of the anti-apoptotic factor Bcl-2.
This effect could be most relevant for treatment of neurodegenerative disor
ders.
5. Lithium inhibits glycogen synthase kinase-3, which is involved in a wide
range of signal transduction pathways. However, this lithium effect occurs
at high concentrations and may be more relevant for its toxic effect.
6. Lithium in low concentrations induces accumulation of PAP, which affects
several cellular processes including RNA processing. However, PAP phosphat
ase is present more in peripheral tissues than in brain. This lithium effec
t could explain some of its peripheral side effects.
7. Chronic lithium administration upregulates glutamate reuptake and thus d
ecreases glutamate availability in synapse. Glutamate is an excitatory neur
otransmitter and its reduction could exert an antimanic effect.
8. Biochemical and clinical experiments are necessary to determine the key
mechanism of lithium efficacy in treatment and prophylaxis of affective dis
orders.